You are here: Industry Insights > Market News > Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference

biospaceMarch 06, 2018

Tag: Bristol-Myers Squibb , Healthcare

Favorites

Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Cowen and Company 38th Annual Global Health Care Conference on Monday, March 12, 2018, in Boston. Giovanni Caforio, chairman and chief executive officer and Fouad Namouni, head of oncology development will answer questions about the company at 2:50 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Register as Visitor to CPhI China 2018!

Previous:AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March

Next:ArQule Reports Fourth Quarter and Full Year 2017 Financial Results

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Ascletis Pharma Inc. announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity.

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference | Pharmasources.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

PeproMene Bio, Inc.has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory (r/r) follicular lymphoma.

You may like
More>>

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 250ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 20ml

Juniper Berries Powder for Healthcare Supplement

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 70ml

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement 200ml

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 2

Nutritional Healthcare Supplement OEM private label Enzyme Juice Prices Fresh Noni Fruit Powder

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 40ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 300ml

Gas Flow Restrictors For Healthcare And Lifesciences

Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference

Related News

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

You may likeMore>>

You may like
More>>